Skip to content
Life Sciences Series B Founded 2017

Solarea Bio

Solarea Bio innovates microbial solutions for human health, focusing on aging-related conditions. The company develops products addressing dietary needs related to rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions associated with aging, leveraging microbiome science to advance health outcomes. Founded in 2017 and headquartered in Cambridge, United States, Solarea Bio has raised…

📍 Cambridge, United States · Nutraceuticals Tech,

Funding snapshot

Last roundSeries B
Amount$10M
Date4 November 2025
Total raised$37M
Team size19

About

Solarea Bio innovates microbial solutions for human health, focusing on aging-related conditions. The company develops products addressing dietary needs related to rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions associated with aging, leveraging microbiome science to advance health outcomes. Founded in 2017 and headquartered in Cambridge, United States, Solarea Bio has raised approximately $37.2M in Series B funding from investors including Illumina, Bold Capital Partners, Viking Global Investors, S2G Investments, Joyance Partners, and Rising Tide Fund. The company combines microbiome research with nutritional science to develop bioactive products that modulate the gut microbiome for therapeutic benefit, addressing the growing intersection of nutrition and medicine for aging populations seeking to maintain mobility and quality of life through microbiome-targeted interventions.

Business model

Gastroenterology > Drugs > Diversified,

Genomics > Applied Genomics > Clinical Genomics > Therapeutics,

Nutraceuticals Tech > Functional Foods and Beverages

Institutional investors

Illumina Bold Capital Partners Viking Global Investors GISEV S2G Investments GG1978 Joyance Partners MassBio Rising Tide Fund Olive Tree Capital

Latest coverage

No articles yet.

Raising like Solarea Bio?

Analyze your pitch deck before your next raise.

Analyze My Deck →